Boston IVF And Ivigen Announce Partnership To Improve Fertility Outcomes

WALTHAM, Mass. & VALENCIA, Spain--(BUSINESS WIRE)--Boston IVF, a leading provider of in vitro fertilization services in the U.S., IviGen LLC^® and its parent company iGenomix^®, worldwide providers of advanced services in reproductive genetics, today announced a partnership which will provide comprehensive genetic testing services to Boston IVF patients.

“IviGen’s mission is to become the leading provider of genetic testing services to the reproductive health community and this agreement represents a great opportunity for us to work with one of the most advanced teams in the world in genetic testing and reproductive health”

“We’re very pleased to be partnering with IviGen, a leader in the field of genetic testing, to provide the most advanced and productive testing services to our couples undergoing reproductive health counseling and treatments, said Dr. Michael Alper, Medical Director and President of Boston IVF. “This partnership will allow Boston IVF to offer the most advanced genetic screening technologies for IVF patients and their embryos, and at a price point that makes these technologies more readily available.”

The relationship brings together Boston IVF’s premier reproductive health services with IviGen’s advanced, genetics-based reproductive health products, including:

• Preimplantation genetic screening (PGS), a test performed in conjunction with IVF to screen embryos for chromosomal abnormalities. Studies suggest PGS can improve IVF pregnancy rates by helping clinicians identify the most viable embryos prior to transfer.
• Preimplantation genetic diagnosis (PGD), a test performed in conjunction with IVF treatment to identify single gene disorders among embryos produced by couples who are at risk of having a child with a particular genetic disease. PGD can help reduce the risk of a particular disorder being passed onto a child.
• Products of conception (POC) testing, which evaluates tissue from a pregnancy loss for chromosome abnormalities in order to help determine cause of the miscarriage. POC testing can help patients and caregivers evaluate future reproductive care options.
• Endometrial receptivity array (ERA^®). ERA evaluates the expression of a group of genes related to endometrial receptivity to determine the optimal timing for embryo transfer and implantation. Early studies suggest that ERA may improve reproductive success for some couples, by identifying the optimal, personalized time for embryo transfer.
• Sperm aneupoloidy test (SAT), a genetic test that determines whether there is an increased incidence of significant chromosome abnormalities in sperm. SAT can help some patients and caregivers evaluate future reproductive care options.

“IviGen’s mission is to become the leading provider of genetic testing services to the reproductive health community and this agreement represents a great opportunity for us to work with one of the most advanced teams in the world in genetic testing and reproductive health,” said David Jimenez, chief executive officer of IviGen and iGenomix. “This partnership also allows us to collaborate in the research and development of new tools to prevent infertility and improve treatment outcomes.”

About Boston IVF

Boston IVF is a leading site for cutting-edge reproductive technologies and exceptional patient care. With more than 50,000 babies born since its inception in 1986, we are proud to be considered among America’s most experienced fertility centers. Boston IVF has offices in Massachusetts as well as Rhode Island, Arizona, New York, Indiana and Maine. At Boston IVF, we respect each patient as an individual and our goal is to offer safe and effective treatments to help couples achieve their goals of building a family.

For more information, please visit www.bostonivf.com

About IviGen

IviGen provides advanced genetic diagnostic services to help couples build healthy families. IviGen’s goal is patient and clinic satisfaction. The company provides superior genetic services that help to improve clinical results: PGS, PGD, ERA^®, POC and Sperm Aneuploidy Test. IviGen is the affiliate of iGenomix in the US. For more information, please visit www.ivigen.com.